文献速递免疫规划

12、18或24月龄加强接种4CMenB后杀菌抗体的持续性及4岁龄接种第五剂疫苗的免疫原性:一项随机对照试验的3期扩展研究

Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial.
PubMed 文献 · Vaccine · 2016-11-30

该3期开放标签多中心扩展研究评估了幼儿期12、18或24月龄加强接种4CMenB后杀菌抗体的持续性,以及4岁龄接种第五剂后的免疫应答。基线时各加强组hSBA滴度≥5的比例对5/99为89-100%,对H44/76为12-35%,对NZ98/254为8-12%,对M10713为53-80%;4岁龄接种一剂后分别升至100%、97-100%、80-95%和84-100%。结论认为无论加强接种年龄如何,幼儿加强后24-36个月出现保护性抗体减弱,但对5/99和M10713靶菌株减弱最不明显,4岁龄加强后出现稳健的记忆应答。

要点

  • 幼儿期12、18或24月龄加强接种4CMenB后24-36个月出现保护性抗体减弱,与加强年龄无关。
  • 对5/99和M10713靶菌株的抗体减弱最不明显。
  • 4岁龄接种第五剂4CMenB后出现稳健的记忆应答。

核心结论

  • 幼儿期加强接种4CMenB后24-36个月出现保护性抗体减弱,无论加强接种年龄如何。
  • 对5/99和M10713靶菌株的抗体减弱最不明显。
  • 4岁龄接种一剂4CMenB后出现稳健的记忆应答。

研究设计与样本

  • 一项3期、开放标签、多中心扩展研究,为随机对照试验的扩展。
  • 研究在四个国家开展:捷克共和国十九个中心、意大利四个中心、西班牙四个中心、英国四个中心。
  • 招募4岁龄儿童,包括未接种过4CMenB的儿童和先前接受过多种3剂婴儿基础免疫程序及幼儿期加强疫苗的儿童(随访组)。
  • 采集静脉血样检测针对四种参考菌株的hSBA:NadA(5/99)、fHbp(H44/76)、PorA(NZ98/254)和NHBA(M10713)。
  • 基线(接种前)检测所有参与者;接种后一个月检测所有未接种过疫苗的参与者和接受2、3、4月龄基础免疫程序的随访组参与者,以及接受2、4、6月龄基础免疫程序的随访组参与者中的三分之一。

主要发现

  • 基线(接种前)时,随访组(n=468)中hSBA滴度≥5的比例对5/99为89-100%,对H44/76为12-35%,对NZ98/254为8-12%,对M10713为53-80%。
  • 基线时未接种过疫苗的对照组(n=206)中hSBA滴度≥5的比例对5/99为5%,对H44/76为0%,对NZ98/254为0%,对M10713为60%。
  • 4岁龄接种一剂4CMenB后,随访组(n=210)中hSBA滴度≥5的比例对5/99为100%,对H44/76为97-100%,对NZ98/254为80-95%,对M10713为84-100%。
  • 接种后未接种过疫苗的对照组(n=192)中hSBA滴度≥5的比例对5/99为89%,对H44/76为70%,对NZ98/254为24%,对M10713为76%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 4CMenB is immunogenic in infants and toddlers. We assessed persistence of human complement serum bactericidal activity (hSBA) following a fourth dose administered at 12, 18 or 24months and characterised the antibody response to a fifth dose administered at 4years of age. METHODS: A phase 3, open label, multi-centre extension to a randomised controlled trial conducted in four countries (number of centres): Czech Republic (nineteen), Italy (four), Spain (four) and the United Kingdom (four). Four-year-old children who were either 4CMenB-naïve or had previously received a variety of 3-dose infant priming schedules and a booster vaccine as toddlers (follow-on group) were recruited. Venous blood samples were obtained to determine hSBA against four reference strains; acting as targets to assess immunity to each of the vaccine antigens, NadA (5/99), fHbp (H44/76), PorA (NZ98/254), and NHBA (M10713) at baseline (prior to vaccination, all participants) and one month following a dose of 4CMenB for all vaccine-naïve and follow-on participants primed with the 2, 3, 4 schedule, and a third of follow-on participants primed with a 2, 4, 6month schedule. RESULTS: At baseline (prior to vaccination), the proportion of participants (n=468) with hSBA titers⩾5 was similar across all followon groups: 89-100% against 5/99; 12-35% for H44/76; 8-12% for NZ98/254 and 53-80% for M10713 compared with 5%, 0%, 0%; and 60% respectively, for the vaccine-naïve controls (n=206). Following a dose of 4CMenB at 4years of age, this increased to 100% (5/99), 97-100% (H44/76), 80-95 % (NZ98/254) and 84-100% (M10713) (n=210), compared with 89%, 70%, 24%, and 76% respectively for vaccine-naïve controls (n=192). CONCLUSION: Waning of protective antibodies occurred 24–36 months after toddler booster regardless of age at boost. This was least marked against target strains 5/99 and M10713. A robust memory response occurred after a booster dose given at 4 years of age.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Iro MA, Snape MD, Voysey M, et al. Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial. Vaccine. 2016. PMID: 27914744. doi:10.1016/j.vaccine.2016.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。